Holder evidence
50
SEC ownership of Aurinia Pharmaceuticals Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001600620.
Lead holder
TANG CAPITAL MANAGEMENT LLC
13D/G signal
TANG CAPITAL MANAGEMENT LLC
Latest evidence
31 Mar 2026
- SEC evidence mix
- 13F, 13D/G, and 3/4/5
- Lead holder
- TANG CAPITAL MANAGEMENT LLC
- Latest large-stake holder
- TANG CAPITAL MANAGEMENT LLC
- Latest evidence date
- 31 Mar 2026
- CIK
- 0001600620
- Symbol
- AUPH on Nasdaq
- Location
- Edmonton, Alberta, Canada
Ownership snapshot
4 facts
Issuer identity
3 facts
Ownership snapshot
Top shareholders of Aurinia Pharmaceuticals Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
TANG CAPITAL MANAGEMENT LLC
13D/G signal
TANG CAPITAL MANAGEMENT LLC
Evidence rows
50
Latest as of
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 9.2%
13D/G row: TANG CAPITAL MANAGEMENT LLC
Showing 1-8 of 50 holder rows.
Rank 1 holder
TANG CAPITAL MANAGEMENT LLC
13F
13D/G
- Ownership
- 9.2%
- Position
- $181.24M
Rank 2 holder
ILJIN SNT Co., Ltd.
13D/G
- Ownership
- 5%
- Position
- $57.51M
Rank 3 holder
ARMISTICE CAPITAL, LLC
13D/G
- Ownership
- 4.5%
- Position
- $51.84M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC |
13F
13D/G
Company
|
9.2%
from 13D/G
|
$181,241,190
12,229,500 shares
|
— | 31 Mar 2026 |
| ILJIN SNT Co., Ltd. |
13D/G
Chin Kyu Huh
|
5%
|
$57,509,241
6,535,141 shares
|
$0 | 11 Aug 2025 |
| ARMISTICE CAPITAL, LLC |
13D/G
|
4.5%
|
$51,840,000
6,400,000 shares
|
$0 | 31 Dec 2024 |
| Kevin Tang |
3/4/5
Director
|
9.2%
|
$173,903,490
12,229,500 shares
|
+$26,278,806 | 27 Feb 2026 |
| BlackRock, Inc. |
13F
Company
|
5.9%
|
$116,270,621
7,845,521 shares
|
— | 31 Mar 2026 |
| NEA Management Company, LLC |
13F
Company
|
3%
|
$58,832,940
3,969,834 shares
|
— | 31 Mar 2026 |
| TWO SIGMA INVESTMENTS, LP |
13F
Company
|
2.6%
|
$50,813,408
3,428,705 shares
|
— | 31 Mar 2026 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
Company
|
2.5%
|
$48,674,334
3,284,368 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$26,068,806.
Buys
$26,278,806
Insiders: 1
Sells
$210,000
Insiders: 1
Net
+$26,068,806
Shares: +2,180,000
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 2,200,000
Shares: 20,000
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 383,561 | 0 | $5,462,271 | $0 | +$5,462,271 |
| 3-6 | 516,439 | 0 | $7,226,535 | $0 | +$7,226,535 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 1,300,000 | 20,000 | $13,590,000 | $210,000 | +$13,380,000 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 28 reporting-owner rows connected to Aurinia Pharmaceuticals Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
28
Lead holder
Kevin Tang
Net 12M change
+$26,068,806
Latest report
18 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Kevin Tang | Director | $173,903,490 | +$26,278,806 | +18% | Filing P/S | 27 Feb 2026 |
| Peter Greenleaf | Chief Executive Officer, Director | $26,151,785 | Mixed | 27 Feb 2026 | ||
| Matthew Maxwell Donley | Chief Operating Officer | $9,667,048 | Mixed | 27 Feb 2026 | ||
| Stephen P. Robertson | Chief Legal Officer | $9,209,177 | Median | 18 May 2026 | ||
| Joseph M. Miller | Chief Financial Officer | $8,190,942 | Mixed | 27 Feb 2026 | ||
| Michael Robert Martin | Chief Business Officer | $2,918,164 | Mixed | 02 Mar 2023 | ||
| Scott Michael Habig | Chief Commercial Officer | $2,423,155 | Filing P/S | 06 Aug 2024 | ||
| Greg Keenan | SVP, Chief Medical Officer | $2,230,243 | -$210,000 | -8.6% | Mixed | 06 Mar 2026 |
| Volker Knappertz | EVP, Research and Development | $1,946,681 | Filing P/S | 27 Feb 2024 | ||
| Ryan Cole | Chief Operating Officer | $1,721,254 | Median | 18 May 2026 | ||
| Michael S. Hearne | Chief Financial Officer | $1,721,254 | Median | 18 May 2026 | ||
| Neil Solomons | Chief Medical Officer | $1,024,131 | Mixed | 02 Mar 2022 | ||
| George M. Milne Jr. | Director | $886,534 | Mixed | 18 May 2023 | ||
| Robert Bindert Huizinga | EVP of Research | $781,208 | Mixed | 02 Mar 2022 | ||
| David R.w. Jayne | Director | $476,287 | Mixed | 21 Nov 2024 | ||
| Jeffrey A. Bailey | Director | $357,112 | Mixed | 21 Nov 2025 | ||
| Craig A. Johnson | Director | $228,802 | Mixed | 21 Nov 2025 | ||
| Jill Leversage | Director | $211,197 | Mixed | 21 Nov 2024 | ||
| Karen L. Smith | Director | $209,123 | Mixed | 21 Nov 2024 | ||
| Ph.D. Daniel Billen | Director | $161,529 | Filing P/S | 21 May 2024 |
Recent insider transactions for Aurinia Pharmaceuticals Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Stephen P. Robertson | AUPH | Common Stock | Award | 22.8% | 115,541 | 621,402 | 18 May 2026 | Direct | ||
| Michael S. Hearne | AUPH | Common Stock | Award | 116,144 | 116,144 | 18 May 2026 | Direct | |||
| Michael S. Hearne | AUPH | Employee Stock Option (right to buy) | Award | 70,230 | 70,230 | 18 May 2026 | Direct | |||
| Ryan Cole | AUPH | Common Stock | Award | 116,144 | 116,144 | 18 May 2026 | Direct | |||
| Ryan Cole | AUPH | Employee Stock Option (right to buy) | Award | 70,230 | 70,230 | 18 May 2026 | Direct | |||
| Greg Keenan | AUPH | Common Stock | Tax liability | -4.96% | -8,069 | 154,449 | 06 Mar 2026 | Direct | ||
| Kevin Tang | AUPH | Common Shares | Purchase | 1.53% | $2,619,438 | $14.22 | 184,208 | 12,229,500 | 03 Mar 2026 | By LP |
| Kevin Tang | AUPH | Common Shares | Purchase | 1.68% | $2,842,833 | $14.26 | 199,353 | 12,045,292 | 02 Mar 2026 | By LP |
| Joseph M. Miller | AUPH | Common Stock | Tax liability | -6.11% | -37,511 | 576,421 | 02 Mar 2026 | Direct | ||
| Matthew Maxwell Donley | AUPH | Common Stock | Tax liability | -5.65% | -40,761 | 680,299 | 02 Mar 2026 | Direct | ||
| Peter S. Greenleaf | AUPH | Common Stock | Tax liability | -5.2% | -100,890 | 1,840,379 | 02 Mar 2026 | Direct | ||
| Stephen P. Robertson | AUPH | Common Stock | Tax liability | -6.73% | -36,525 | 505,861 | 02 Mar 2026 | Direct | ||
| Kevin Tang | AUPH | Common Shares | Purchase | 4.56% | $7,226,535 | $13.99 | 516,439 | 11,845,939 | 27 Feb 2026 | By LP |
| Joseph M. Miller | AUPH | Common Stock | Award | 10.3% | 57,229 | 613,932 | 27 Feb 2026 | Direct | ||
| Joseph M. Miller | AUPH | Employee Stock Option (right to buy) | Award | 95,700 | 95,700 | 27 Feb 2026 | Direct | |||
| Matthew Maxwell Donley | AUPH | Common Stock | Award | 8.77% | 58,160 | 721,060 | 27 Feb 2026 | Direct | ||
| Matthew Maxwell Donley | AUPH | Employee Stock Option (right to buy) | Award | 97,256 | 97,256 | 27 Feb 2026 | Direct | |||
| Peter S. Greenleaf | AUPH | Common Stock | Award | 11.3% | 196,403 | 1,941,269 | 27 Feb 2026 | Direct | ||
| Peter S. Greenleaf | AUPH | Employee Stock Option (right to buy) | Award | 328,424 | 328,424 | 27 Feb 2026 | Direct | |||
| Greg Keenan | AUPH | Common Stock | Award | 33.3% | 40,586 | 162,518 | 27 Feb 2026 | Direct | ||
| Greg Keenan | AUPH | Employee Stock Option (right to buy) | Award | 67,870 | 67,870 | 27 Feb 2026 | Direct | |||
| Stephen P. Robertson | AUPH | Common Stock | Award | 12.2% | 59,090 | 542,386 | 27 Feb 2026 | Direct | ||
| Stephen P. Robertson | AUPH | Employee Stock Option (right to buy) | Award | 98,813 | 98,813 | 27 Feb 2026 | Direct | |||
| Matthew Maxwell Donley | AUPH | Common Stock | Tax liability | -4.73% | -32,901 | 662,900 | 20 Feb 2026 | Direct | ||
| Peter S. Greenleaf | AUPH | Common Stock | Tax liability | -5.43% | -100,171 | 1,744,866 | 20 Feb 2026 | Direct | ||
| Joseph M. Miller | AUPH | Common Stock | Tax liability | -5.5% | -32,424 | 556,703 | 20 Feb 2026 | Direct | ||
| Stephen P. Robertson | AUPH | Common Stock | Tax liability | -6.69% | -34,638 | 483,296 | 20 Feb 2026 | Direct | ||
| Greg Keenan | AUPH | Common Stock | Tax liability | -8.65% | -11,552 | 121,932 | 02 Feb 2026 | Direct | ||
| Stephen P. Robertson | AUPH | Common Stock | Tax liability | -7.23% | -40,385 | 517,934 | 02 Jan 2026 | Direct | ||
| Stephen P. Robertson | AUPH | Common Stock | Award | 9.54% | 48,558 | 557,434 | 02 Jan 2026 | Direct | ||
| Matthew Maxwell Donley | AUPH | Common Stock | Tax liability | -5.79% | -42,787 | 695,801 | 02 Jan 2026 | Direct | ||
| Matthew Maxwell Donley | AUPH | Common Stock | Award | 7.96% | 54,166 | 734,631 | 02 Jan 2026 | Direct | ||
| Joseph M. Miller | AUPH | Common Stock | Tax liability | -6.38% | -40,161 | 589,127 | 02 Jan 2026 | Direct | ||
| Joseph M. Miller | AUPH | Common Stock | Award | 8.49% | 49,038 | 626,399 | 02 Jan 2026 | Direct | ||
| Peter S. Greenleaf | AUPH | Common Stock | Tax liability | -5.78% | -113,169 | 1,845,037 | 02 Jan 2026 | Direct | ||
| Peter S. Greenleaf | AUPH | Common Stock | Award | 9.24% | 165,384 | 1,954,329 | 02 Jan 2026 | Direct | ||
| Jeffrey A. Bailey | AUPH | Common Shares | Tax liability | -10.6% | -2,716 | 22,775 | 21 Nov 2025 | Direct | ||
| Craig A. Johnson | AUPH | Common Shares | Tax liability | -29.3% | -6,039 | 14,592 | 21 Nov 2025 | Direct | ||
| Kevin Tang | AUPH | Common Shares | Purchase | 1.8% | $2,336,000 | $11.68 | 200,000 | 11,329,500 | 05 Aug 2025 | By LP |
| Kevin Tang | AUPH | Common Shares | Purchase | 0.91% | $1,134,000 | $11.34 | 100,000 | 11,129,500 | 04 Aug 2025 | By LP |
| Kevin Tang | AUPH | Common Shares | Purchase | 9.97% | $10,120,000 | $10.12 | 1,000,000 | 11,029,500 | 01 Aug 2025 | By LP |
| Greg Keenan | AUPH | Common Stock | Sale | -13% | $210,000 | $10.50 | -20,000 | 133,484 | 01 Aug 2025 | Direct |
* indicates a reported price that failed the local validity check.